knowledge -WSS

knowledge

author：entertainment 2025-09-30 11:58:18 - browse：67

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Overprescribed: High cost isn't America's only drug problem

WSS

AMAs digital advisors table RPM coding reform proposal, again

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

ACIP vaccine advisory panel sees its vacancies filled

Multiple sclerosis has subtypes with different best treatments: study

Resistance to opioid

Researchers test human milk's ability to repair gut microbiome

knowledge

knowledge

leisure time

Cancer drug shortages should be causing more outrage

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AMAs digital advisors table RPM coding reform proposal, again

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

How to save PrEP access — and even expand it

Why don't Americans have at

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Alzheimer's risk factor APOE4 may be a distinct form of the disease

focus

Artificial intelligence use in health care faces greater scrutiny in 2024

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Artificial intelligence use in health care faces greater scrutiny in 2024

Hundreds died while taking an arthritis drug, but nobody alerted patients

Congress must protect the remaining independent doctors

Study gives hint on South Asians’ higher risk of cardiovascular disease

Wikipedia

hotspot

entertainment

focus